Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories established Pharmaceutical Products — Segment Cost of Products Sold ($M) ($M)
Postgres DB segment_values + Form 10-K/10-Q XBRL
Latest, FY2025
-2,615
Period ended Dec 31, 2025
Change on a year earlier
+7.0%
-2,444 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Established Pharmaceutical Products — Segment Cost of Products Sold ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -2,615 | +7.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | -2,444 | +3.7% | Form 10-K (filed 2025-02-21) ↗ |
| FY2023 | Dec 31, 2023 | -2,357 | +2.3% | Form 10-K (filed 2025-02-21) ↗ |
| FY2022 | Dec 31, 2022 | -2,305 | – | Form 10-K (filed 2025-02-21) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Established Pharmaceutical Products — Segment Cost of Products Sold ($M) ($M), annual FY2022–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/db-seg-cogs-epd
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.